Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo

BACKGROUND: Imatinib is a direct and potent inhibitor of the constitutively active tyrosine kinase, breakpoint cluster region-Abelson (Bcr-Abl), which is central to the pathogenesis of chronic myeloid leukaemia (CML) patients. As such, imatinib has become the front-line treatment for CML patients. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Bright, S A, McElligott, A M, O'Connell, J W, O'Connor, L, Carroll, P, Campiani, G, Deininger, M W, Conneally, E, Lawler, M, Williams, D C, Zisterer, D M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2869169/
https://www.ncbi.nlm.nih.gov/pubmed/20407438
http://dx.doi.org/10.1038/sj.bjc.6605670

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2869169/
https://www.ncbi.nlm.nih.gov/pubmed/20407438
http://dx.doi.org/10.1038/sj.bjc.6605670

Ejemplares similares